In a cross-section study the levels of urine laminin P1 expressed as a laminin P1:creatinine ratio were determined in 25 patients with superficial (noninvasive) transitional cell carcinoma (TCC) of the bladder, 12 patients with invasive TCC, 15 patients with inflammatory bladder diseases and 50 healthy controls. The mean of laminin P1·creatinine ratios in invasive TCC patients (4.83 ± 3.05 U/mol creatinine) significantly differed from those of superficial TCC (2.60 ± 1.07 U/mol creatinine), inflammatory bladder disorders (2.38 ± 1.74 U/mol creatinine) and controls (2.47 ± 0.86 U/mol creatinine) (p < 0.03). At the individual patient level 7 out of 12 patients with invasive TCC, but only 1 out of 25 patients with superficial TCC, showed laminin P1 urine levels above the normal range (0.75–4.18 U/mol creatinine), thus giving a 58% sensitivity and a 96% specificity of laminin P1 urine assessment in the discrimination between noninvasive and invasive disease. Given a 20–24% prior chance of invasive disease at initial diagnosis detection of elevated urine laminin P1 in TCC patients raises the posttest chance of invasive disease to 87.5%.

This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.